Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

11.91 +0.08 (+0.68%)
Streaming Delayed Price Updated: 1:25 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Eyes Growth Despite Tariffs
AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow expected. 
Via Benzinga
Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&P 500... 
Via Benzinga
Topics Stocks
Why Did AngioDynamics Stock Pop Today?
Even 37 years after its founding, AngioDynamics still can't earn a profit. 
Via The Motley Fool
Earnings Scheduled For October 2, 2025
 
Via Benzinga
What's Next: AngioDynamics's Earnings Preview
 
Via Benzinga
Earnings Outlook For AngioDynamics
 
Via Benzinga
What's Fueling The Momentum In AngioDynamics Stock?
Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter. 
Via Benzinga
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
 
Via Benzinga
AngioDynamics Inc (NASDAQ:ANGO) Surpasses Q1 Earnings Estimates and Raises Fiscal 2026 Outlook
AngioDynamics (ANGO) beat Q1 FY2026 earnings and revenue estimates, driven by strong Med Tech growth. The company also raised its full-year financial outlook. 
Via Chartmill
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
From AngioDynamics, Inc.
Via Business Wire
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
S&P 500 Closes At Record High: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone
CNN Business Fear & Greed Index at 52.3, remaining in Neutral zone. Stocks close higher despite economic headwinds, with record S&P 500 level. 
Via Benzinga
Topics Stocks
AngioDynamics, Globant And 3 Stocks To Watch Heading Into Thursday
US stock futures mixed, with attention on earnings reports from companies like AngioDynamics, Grindr, and Entero Therapeutics. 
Via Benzinga
Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings
 
Via Benzinga
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
From AngioDynamics, Inc.
Via Business Wire
Recent Report Shows That Rep. Debbie Wasserman Schultz Bought Up to $15K Worth of Ichor Holdings Stock
 
Via Benzinga
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
From AngioDynamics, Inc.
Via Business Wire
A Congress Member Sold Up To $30K In AngioDynamics Stock: Here's What You Need To Know
 
Via Benzinga
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
From AngioDynamics, Inc.
Via Business Wire
Why AngioDynamics Stock Popped, Then Dropped Today
AngioDynamics' big Q4 earnings beat wasn't as impressive as it first seemed. 
Via The Motley Fool
Topics Earnings
AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting
AngioDynamics expects a $4 million-$6 million impact from tariffs. Still, it's "profitable," CEO Jim Clemmer says. 
Via Benzinga
Topics World Trade
AngioDynamics (ANGO) Q4 2025 Earnings Transcript
Via The Motley Fool
Topics World Trade
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For July 15, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Monday's after-hours session.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.